Archive · 18 Jun 2025
Novartis, MSN Settle Entresto Patent, Divi's Lab Shares Increase
Imagine a big company, Novartis, makes a very important medicine called Entresto for people with heart problems.
Another company, MSN, wanted to make a cheaper version.
Novartis and MSN had a legal battle about patents, which are like special rights for medicines.
Now, they've reached an agreement.
Divi's Laboratories makes a key ingredient for Entresto.
This agreement is good news for Divi's, and its shares went up.
However, when MSN launches its generic version, it may impact Divi's earnings.
The main patent expires in July 2025.
Novartis and MSN settled a patent dispute regarding the heart failure drug Entresto.
Divi's Laboratories is a key supplier of active pharmaceutical ingredients (APIs) for Entresto.
The main Entresto patent is set to expire in July 2025.
Shares of Divi's Laboratories increased on Wednesday, June 18th.
Divi's Laboratories' earnings from Entresto API could be impacted by generic competition.
- Who
- Novartis and MSN, with Divi's Laboratories as a key supplier of Entresto's APIs.
- What
- Novartis and MSN settled a patent dispute over the heart failure drug Entresto.
- When
- The settlement occurred; shares of Divi's Laboratories rose on Wednesday, June 18.
- Where
- Not explicitly mentioned.
- Why
- To resolve the legal battle and determine the future of Entresto's generic competition.
Novartis
MSN
Patent Validity and Market Entry
Novartis
Original Manufacturer's Perspective: Preserving Market Exclusivity
MSN
Generic Manufacturer's Perspective: Seeking Market Entry
- Drug
- Entresto
- Companies Involved
- Novartis, MSN, Divi's Laboratories
- Patent Status
- Main patent expires in July 2025
- Divi's FY25 Earnings (est.)
- ₹1,200 crore
- Divi's FY26 Earnings (est., with generic)
- ₹700 crore
- Divi's Laboratories' share increase (June 18)
- 1.7%
- Entresto's Sales (approx.)
- $6 billion